TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-Week, Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Irritability Associated With Autistic Disorder
Brief Summary: This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.


Options:
A: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
C: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-Week, Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Irritability Associated With Autistic Disorder
Brief Summary: This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.


Options:
A: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin
Brief Summary: The purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. We anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
B: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin
Brief Summary: The purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. We anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.


Options:
A: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide
C: Intervention Type: DRUG; Name: metformin XR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clomiphene citrate; Assigned to Arm(s): N/A
D: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial
Brief Summary: This project is being undertaken to test the hypothesis that implementing a community based package of care for women with hypertensive disorders of pregnancy will result in overall improvement in maternal and neonatal outcomes. This is based on the premise that there are three main modifiable reasons why women (and their fetuses/newborns) die due to pregnancy complications: 1) delays by the woman herself in recognizing the seriousness of her condition; 2) delays in her being assessed and then transported to a center capable of providing effective and life-saving interventions; and 3) delays in the health facility in providing those interventions. The treatments for pre-eclampsia that are poorly accessed in LMIC are 1) magnesium sulfate (MgSO4) for prevention and treatment of the grand mal seizures of eclampsia; 2) oral antihypertensive medication to lower maternal BP to reduce the risk of stroke.

The CLIP pilot and definitive cRCT will investigate whether the community level intervention including implementation of the CLIP package (oral antihypertensive therapy when indicated, intramuscular (i.m.) MgSO4 when indicated; and appropriate referral to an CEmOC facility when indicated) of care will reduce the incidence of all-cause maternal morbidity and mortality.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MISOPROSTOL; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): MISOPROSTOL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Community Engagement, Device: PIERS on the Move mHealth decision aid, Drug: Magnesium Sulfate, Drug: Methyldopa | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Engagement; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: PIERS on the Move mHealth decision aid; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Methyldopa; Assigned to Arm(s): Intervention
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Ergometrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ergometrine | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Ergometrine; Assigned to Arm(s): Ergometrine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Brief Summary: To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).


Options:
A: Arm Label: UroLift System; Type: ACTIVE_COMPARATOR; Interventions: Device: UroLift System | Arm Label: Cystoscopy; Type: SHAM_COMPARATOR; Interventions: Other: Cystoscopy | Arm Label: Crossover; Type: ACTIVE_COMPARATOR; Interventions: Device: Crossover | Intervention Type: DEVICE; Name: UroLift System; Assigned to Arm(s): UroLift System | Intervention Type: OTHER; Name: Cystoscopy; Assigned to Arm(s): Cystoscopy | Intervention Type: DEVICE; Name: Crossover; Assigned to Arm(s): Crossover
B: Arm Label: Prostatic artery embolization; Type: EXPERIMENTAL; Interventions: Procedure: Prostatic artery embolization | Arm Label: Conventional monopolar transurethral prostatectomy; Type: OTHER; Interventions: Procedure: monopolar transurethral prostatectomy | Intervention Type: PROCEDURE; Name: Prostatic artery embolization; Assigned to Arm(s): Prostatic artery embolization | Intervention Type: PROCEDURE; Name: monopolar transurethral prostatectomy; Assigned to Arm(s): Conventional monopolar transurethral prostatectomy
C: Arm Label: UroLift System; Type: ACTIVE_COMPARATOR; Interventions: Device: UroLift System | Arm Label: Transurethral Resection of the Prostate; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transurethral Resection of the Prostate | Intervention Type: DEVICE; Name: UroLift System; Assigned to Arm(s): UroLift System | Intervention Type: PROCEDURE; Name: Transurethral Resection of the Prostate; Assigned to Arm(s): Transurethral Resection of the Prostate
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: Rezum System | Arm Label: Control; Type: OTHER; Interventions: Procedure: Rigid Cystoscopy | Intervention Type: DEVICE; Name: Rezum System; Assigned to Arm(s): Treatment | Intervention Type: PROCEDURE; Name: Rigid Cystoscopy; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety
Brief Summary: Selegiline is superior to placebo in improving psychological and physical functioning in patients with Borderline Personality Disorder.


Options:
A: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Placebo (for Selegiline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Selegiline) | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Selegiline | Intervention Type: DRUG; Name: Placebo (for Selegiline); Assigned to Arm(s): Placebo (for Selegiline)
C: Arm Label: Cognitive Analytic Informed Brief Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive analytic informed brief therapy | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive analytic informed brief therapy; Assigned to Arm(s): Cognitive Analytic Informed Brief Therapy
D: Arm Label: Dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Arm Label: alternative psychotherapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy (DBT); Assigned to Arm(s): Dialectical behavior therapy, alternative psychotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety
Brief Summary: Selegiline is superior to placebo in improving psychological and physical functioning in patients with Borderline Personality Disorder.


Options:
A: Arm Label: Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Placebo (for Selegiline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Selegiline) | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Selegiline | Intervention Type: DRUG; Name: Placebo (for Selegiline); Assigned to Arm(s): Placebo (for Selegiline)
B: Arm Label: Botulinum toxin A; Type: ACTIVE_COMPARATOR; Interventions: Drug: incobotulinumtoxin A | Arm Label: Acupuncture; Type: OTHER; Interventions: Procedure: Acupuncture | Intervention Type: DRUG; Name: incobotulinumtoxin A; Assigned to Arm(s): Botulinum toxin A | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture
C: Arm Label: short-term dynamic therapy; Type: EXPERIMENTAL; Interventions: Behavioral: short-term dynamic therapy | Arm Label: long-term dynamic therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: long-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: short-term dynamic therapy; Assigned to Arm(s): short-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: long-term dynamic therapy; Assigned to Arm(s): long-term dynamic therapy
D: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients
Brief Summary: The purpose of this 5-year interventional study is to design, implement, and evaluate the effectiveness of an intervention aimed at facilitating prognosis communication and end-of-life care decision-making to increase the extent of congruence between the patient's preferred and actual EOL care received and patients' and family caregivers' QOL and psychological well-being, reduce futile aggressive healthcare resources utilization at end-of-life, and facilitate bereavement adjustment.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Loop | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Loop; Assigned to Arm(s): Intervention Group
B: Arm Label: Attention usual care intervention; Type: SHAM_COMPARATOR; Interventions: Behavioral: Attention usual care | Arm Label: Interactive advance care planning; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive advance care planning | Intervention Type: BEHAVIORAL; Name: Interactive advance care planning; Assigned to Arm(s): Interactive advance care planning | Intervention Type: BEHAVIORAL; Name: Attention usual care; Assigned to Arm(s): Attention usual care intervention
C: Arm Label: Early Palliative Care; Type: EXPERIMENTAL; Interventions: Other: early palliative care | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: early palliative care; Assigned to Arm(s): Early Palliative Care
D: Arm Label: communication lecture; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: communication lecture | Arm Label: lecture plus CD-ROM; Type: EXPERIMENTAL; Interventions: Behavioral: lecture plus CD-ROM | Intervention Type: BEHAVIORAL; Name: communication lecture; Assigned to Arm(s): communication lecture | Intervention Type: BEHAVIORAL; Name: lecture plus CD-ROM; Assigned to Arm(s): lecture plus CD-ROM

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PICO Versus Standard Dressing on Groin Incisions After Vascular Surgery - a Prospective Randomized Trial (INVIPS Trial)
Brief Summary: The wound infection rate in the groin after vascular surgery has been denoted to be high since the wound surveillance register started in 2005. The current wound infection rate based on a validation study was 22.9% (24/105 patients with groin incision(s) between 1 March to 30 June in 2012). This randomized controlled trial aims to evaluate if negative pressure wound therapy on closed inguinal incisions (INPWT) after vascular surgical procedures can reduce the risk for surgical site infections and other wound complications.


Options:
A: Arm Label: Standard wound dressing OPEN; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PICO dressing OPEN; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy with PICO (Smith & Nephew) | Arm Label: Standard dressing EVAR; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PICO dressing EVAR; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy with PICO (Smith & Nephew) | Intervention Type: DEVICE; Name: Negative pressure wound therapy with PICO (Smith & Nephew); Assigned to Arm(s): PICO dressing EVAR, PICO dressing OPEN
B: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection
C: Arm Label: Vacuum Assisted Closure®; Type: EXPERIMENTAL; Interventions: Device: Vacuum Assisted Closure® | Arm Label: Standard conventional wound therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard conventional wound therapy | Intervention Type: DEVICE; Name: Vacuum Assisted Closure®; Assigned to Arm(s): Vacuum Assisted Closure® | Intervention Type: OTHER; Name: Standard conventional wound therapy; Assigned to Arm(s): Standard conventional wound therapy
D: Arm Label: Vacuum-assisted closure (VAC); Type: EXPERIMENTAL; Interventions: Device: Vacuum-assisted closure | Arm Label: Standard sterile dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard sterile dressing | Intervention Type: DEVICE; Name: Vacuum-assisted closure; Assigned to Arm(s): Vacuum-assisted closure (VAC) | Intervention Type: DEVICE; Name: Standard sterile dressing; Assigned to Arm(s): Standard sterile dressing

Answer: A